NIH's $95.8M biomedical research contract awarded to PPD Development LP shows mixed value and limited competition

Contract Overview

Contract Amount: $95,837,694 ($95.8M)

Contractor: PPD Development LP

Awarding Agency: Department of Health and Human Services

Start Date: 2010-02-01

End Date: 2017-01-31

Contract Duration: 2,556 days

Daily Burn Rate: $37.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 4

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: BIOMEDICAL (BASIC)

Place of Performance

Location: WILMINGTON, NEW HANOVER County, NORTH CAROLINA, 28401

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $95.8 million to PPD DEVELOPMENT LP for work described as: BIOMEDICAL (BASIC) Key points: 1. Contract value of $95.8 million over its life suggests significant investment in biomedical research. 2. The award to a single contractor, PPD Development LP, raises questions about the extent of competition. 3. A 'definitive contract' type with 'cost plus fixed fee' pricing can sometimes lead to cost overruns. 4. The contract duration of 2556 days (approximately 7 years) indicates a long-term need for these services. 5. The North Carolina location for performance might have implications for regional economic impact. 6. The absence of small business set-asides warrants further investigation into subcontracting opportunities.

Value Assessment

Rating: fair

Benchmarking the value of this $95.8 million contract is challenging without more specific details on the scope of biomedical research services provided. However, the 'cost plus fixed fee' pricing structure, while common for R&D, carries inherent risks of cost escalation compared to fixed-price contracts. The relatively high number of modifications (4) could indicate scope changes or challenges in initial planning, potentially impacting overall value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under 'full and open competition,' suggesting that multiple bidders were theoretically allowed to compete. However, the data does not specify the number of bids received or the evaluation process. The fact that it resulted in a definitive contract with a single awardee implies that PPD Development LP was selected as the most advantageous offer.

Taxpayer Impact: While full and open competition is ideal for price discovery, the ultimate benefit to taxpayers depends on the rigor of the evaluation and negotiation process to ensure the best value was secured.

Public Impact

This contract supports critical biomedical research, potentially leading to advancements in health and medicine. The primary beneficiary is the National Institutes of Health (NIH) and the broader scientific community. Services are performed in North Carolina, potentially creating or sustaining jobs in the life sciences sector there. The research conducted could have long-term public health implications, benefiting society broadly.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns due to 'cost plus fixed fee' pricing structure.
Limited insight into the number of bidders and the competitive landscape despite 'full and open' designation.
The number of contract modifications (4) may indicate scope creep or initial underestimation of requirements.
Lack of explicit small business participation noted, requiring further review of subcontracting plans.

Positive Signals

Awarded under 'full and open competition,' theoretically allowing broad market participation.
The significant funding indicates a high priority placed on the biomedical research area by NIH.
The long contract duration suggests a stable and ongoing need for these specialized research services.

Sector Analysis

This contract falls within the Research and Development sector, specifically focusing on physical, engineering, and life sciences. The biomedical research market is substantial, driven by government funding and private investment in healthcare innovation. Contracts like this are crucial for advancing scientific knowledge and developing new therapies. Comparable spending benchmarks would typically be found within NIH's broader R&D portfolio and agency-specific funding announcements for similar research areas.

Small Business Impact

The data indicates that this contract was not set aside for small businesses (ss: false, sb: false). While awarded under full and open competition, there is no explicit mention of small business subcontracting goals or achievements. Further analysis would be needed to determine if PPD Development LP has a robust subcontracting plan that includes small businesses, which is crucial for fostering a diverse supplier base and ensuring opportunities for smaller firms in the federal contracting ecosystem.

Oversight & Accountability

Oversight for this contract would primarily reside with the National Institutes of Health (NIH), a component of the Department of Health and Human Services. Accountability measures are typically embedded within the contract terms, including performance standards, reporting requirements, and payment schedules tied to milestones. Transparency is facilitated through contract databases like FPDS, though detailed performance metrics and specific oversight activities are often internal. The potential for Inspector General review exists, particularly concerning financial management and adherence to contract terms.

Related Government Programs

NIH Research and Development Contracts
Biomedical Research Grants
Life Sciences R&D Services
Department of Health and Human Services Contracts

Risk Flags

Potential for cost overruns
Limited competition transparency
Lack of explicit small business participation details

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $95.8 million to PPD DEVELOPMENT LP. BIOMEDICAL (BASIC)

Who is the contractor on this award?

The obligated recipient is PPD DEVELOPMENT LP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $95.8 million.

What is the period of performance?

Start: 2010-02-01. End: 2017-01-31.

What specific types of biomedical research were conducted under this contract, and what were the key deliverables?

The contract, identified by NAICS code 541712 (Research and Development in the Physical, Engineering, and Life Sciences except Biotechnology), suggests a broad scope within biomedical R&D. Specific deliverables would typically be detailed in the Statement of Work (SOW) appended to the contract. These could range from preclinical studies, drug discovery and development support, clinical trial research services, to development of diagnostic tools or biotechnological processes. Without access to the SOW, the precise nature of the research and its tangible outputs remain unspecified. However, given the funding level and duration, it likely involved complex, multi-phase research projects critical to NIH's mission.

How does the 'cost plus fixed fee' (CPFF) pricing structure compare to other contract types for similar R&D services, and what are the associated risks?

The Cost Plus Fixed Fee (CPFF) structure is common for research and development contracts where the scope of work is not precisely defined at the outset, allowing for flexibility as research progresses. The government pays the contractor's actual allowable costs plus a fixed fee representing profit. Compared to fixed-price contracts, CPFF offers less cost certainty for the government and can incentivize contractors to incur more costs, as the fee is a percentage of costs or a fixed amount regardless of final cost. Risks include potential cost overruns if initial estimates are inaccurate or if the research proves more complex than anticipated. However, it also allows for adaptation to evolving scientific understanding, which is crucial in R&D.

What was the total number of bids received for this contract, and how did PPD Development LP's proposal compare to others?

The contract was awarded under 'full and open competition,' which theoretically allows any responsible source to submit an offer. However, the provided data does not specify the number of bids received. To assess the competitiveness, one would need to consult the contract award documentation or agency procurement files. Without this information, it's difficult to definitively state how many other entities competed or the specific strengths of PPD Development LP's proposal that led to the award. The fact that it resulted in a definitive contract with one awardee suggests PPD Development LP was deemed the best value offer among those submitted.

What is the historical spending pattern for similar biomedical R&D services by the NIH or other agencies?

The NIH is a major funder of biomedical R&D, with annual budgets in the tens of billions of dollars, a significant portion of which is awarded through contracts and grants. Historical spending on contracts for services like those potentially covered by this award (NAICS 541712) has been substantial and generally increasing, reflecting the growing complexity and cost of scientific research and the government's commitment to advancing health. Agencies like the National Science Foundation (NSF) and the Department of Defense also fund R&D, but NIH is the primary agency for biomedical research. Trends show a consistent demand for contract research organizations (CROs) to support various stages of research and development.

Are there any performance issues or contractor disputes associated with PPD Development LP on this or similar federal contracts?

Assessing contractor performance issues or disputes typically requires reviewing contract performance reports, past performance evaluations, and any formal claims or litigation records. This specific data set does not include such information. PPD Development LP (now part of Labcorp Drug Development) is a large contract research organization that has held numerous federal contracts over the years. A comprehensive review would involve searching databases like the Contractor Performance Assessment Reporting System (CPARS) and legal dockets for any documented issues. Without this specific data, it's impossible to ascertain any past performance problems.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: NIAID DAIDS NIH 2008045

Offers Received: 4

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: PPD Development L.P.

Address: 929 N FRONT ST, WILMINGTON, NC, 28401

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $160,507,292

Exercised Options: $95,837,694

Current Obligation: $95,837,694

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline